MOSKOWITZ FAMILY LLC v. GLOBUS MEDICAL, INC.

District Court, E.D. Pennsylvania·Decided August 25, 2021·No. 2:20-cv-03271·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA __________________________________________ : MOSKOWITZ FAMILY LLC : : CIVIL ACTION Plaintiff, : : v. : No. 20-3271 GLOBUS MEDICAL, INC. : : Defendants. : _________________________________________ :

Goldberg, J. August 25, 2021

MEMORANDUM OPINION

Before me is a patent infringement case wherein Plaintiff Moskowitz Family LLC (“Plaintiff”) alleges that Defendant Globus Medical, Inc. (“Defendant”) has infringed eight of Plaintiff’s patents. The parties currently seek construction of ten disputed terms in seven of the patents pursuant to Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed. Cir. 1995), aff’d, 517 U.S. 370 (1996) (“Markman”). The disputed claim terms are construed as indicated in this Memorandum and accompanying Order. I. FACTUAL BACKGROUND

A. Spinal Fusion Procedures and the Parties

The patents in question pertain to spinal implants. By way of background, the human spine is composed of vertically arranged bones—vertebrae—separated by cartilaginous intervertebral discs. The vertebrae are divided into three portions: (1) the uppermost seven vertebrae called the cervical spine; (2) twelve middle vertebrae called the thoracic spine; and (3) the five bottom vertebrae called the lumbar spine. Two pedicle bones dorsally extend from each vertebra and form an arch that protects the spinal cord. In some individuals, the cartilaginous disc between vertebrae may wear, causing pain and pressure on the spinal cord. For those individuals, spinal fusion surgery may offer relief. The procedure permanently connects two or more spinal vertebrae to improve spinal stability, correct deformations, and reduce pain. The procedure, however, can result in adverse patient outcomes

such as high-impaction, neural or vascular injury, esophageal injuries, excessive blood loss, prolonged surgical duration, prolonged recovery, and incomplete return to work results. These adverse events result from static and non-expandable implants, misplaced implants, and implant pull-out after the operation. Plaintiff patents minimally invasive spinal implants that are designed to reduce adverse outcomes in spinal fusion patients. Plaintiff’s inventions include minimal impaction, steerable, and custom-fit intervertebral implants that reduce musculoskeletal disruption and nerve root retraction during and after the procedure. Defendant also is a spinal fusion company that sells intervertebral spinal implants. B. Plaintiff’s Patents

From January 15, 2013 through November 19, 2019, the United States Patent and Trademark Office (“PTO”) issued the eight patents at issue here, which Plaintiff owns by assignment. (First Am. Compl. ¶¶ 17-24.) These patents are directed to intervertebral spinal implant screws, staples, and expandable implant systems. U.S. Patent Nos. 8,353,913 (the “‘913 patent”), 10,307,268 (the “‘268 patent”), and 10,478,319 (the “‘319 patent”) are for tools used for manipulating and inserting spacers into a disc space between two vertebral bodies to facilitate bone and screw fusion. U.S. Patent No. 9,889,022 (the “‘022 patent”) is for an intervertebral screw guide and fixation apparatus for insertion into a disc space between two vertebrae to encourage bone and screw fusion. U.S. Patent No. 10,028,740 (the “‘740 patent”) claims a “curvilinear nail screw,” a holding structure that is implanted into a vertebra and around the pedicle bones to avoid penetrating them, which allegedly reduces risks associated from prior inventions that inserted into pedicle bones. U.S. Patent No. 10,251,643 (the “‘643 patent”) relates to an intervertebral mechanism that expands between vertebral bodies and engages vertebral endplates to keep the mechanism in place. U.S. Patent No. 10,076,367 (the “‘367 patent”) is for a bidirectional system

inserted between vertebrae to facilitate their linking and fusion. Finally, U.S. Patent No. 10,376,386 (the “‘386 patent”) claims a spinal staple with a curved base and ridged spikes that hinder the staple’s removal. C. Procedural Background

According to the Complaint, on June 3, 2015, Plaintiff’s counsel sent a letter to Defendant’s General Counsel that identified the ‘913 patent and the patent application for the ‘022 patent, which at the time was pending at the PTO. (First Am. Compl. ¶ 26.) In the letter, Plaintiff identified additional pending patent applications, of which the remaining patents at issue are continuations. (Id.) The parties failed to reach an agreement, and thereafter the PTO issued the seven pending patent applications. (Id. ¶¶ 17-24, 27-29.) Plaintiff alleges that Defendant has infringed the eight patents listed above and contained in the June 3, 2015 letter through selling various Globus products. (Id. ¶¶ 30.) Plaintiff initiated this action on November 20, 2019, the day after the eighth patent—the ‘319 patent—issued.1 On April 14, 2021, it filed its First Amended Complaint, setting forth allegations of direct infringement, inducement of infringement, contributory infringement, and willful infringement.

1 Plaintiff initially filed the action in the United States District Court for the Western District of Texas, but on July 2, 2020, the case was transferred to the Eastern District of Pennsylvania. (Doc. No. 50.) On May 13, 2021, the parties submitted opening claim construction briefs setting forth their positions on ten disputed claim terms in seven of the eight patents at issue.2 I held a Markman hearing regarding these terms on July 27, 2021. Having fully reviewed the parties’ briefing and evidentiary submissions, I now set forth the legal construction of the disputed claim terms.

II. STANDARD OF REVIEW

The first step in a patent infringement analysis is to define the meaning and scope of the claims of the patent. Markman, 52 F.3d at 976. Claim construction, which serves this purpose, is a matter of law exclusively for the court. Id. at 979. “‘[T]here is no magic formula or catechism for conducting claim construction.’ Instead, the court is free to attach the appropriate weight to appropriate sources ‘in light of the statutes and policies that inform patent law.’” SoftView LLC v. Apple Inc., No. 10-389, 2013 WL 4758195, at *1 (D. Del. Sept. 4, 2013) (quoting Phillips v. AWH Corp., 415 F.3d 1303, 1324 (Fed. Cir. 2005)). “It is a bedrock principle of patent law that the claims of a patent define the invention to which the patentee is entitled the right to exclude.” Phillips, 415 F.3d at 1312 (internal quotation marks omitted). The focus of a court’s analysis must therefore begin and remain on the language of the claims, “for it is that language that the patentee chose to use to ‘particularly point[ ] out and distinctly claim[ ] the subject matter which the patentee regards as his invention.’” Interactive Gift Express, Inc. v. Compuserve, Inc., 256 F.3d 1323, 1331 (Fed. Cir. 2001) (quoting 35 U.S.C. ‘112, & 2). The terms used in the claims bear a “heavy presumption” that they mean what they say and have their ordinary and customary meaning. Texas Digital Sys., Inc. v. Telegeniz, Inc., 308 F.3d 1193, 1202 (Fed. Cir. 2002). That ordinary meaning “is the meaning that the term would have to

2 The ‘319 patent does not contain any of the disputed claim terms.

Free access — add to your briefcase to read the full text and ask questions with AI

MOSKOWITZ FAMILY LLC v. GLOBUS MEDICAL, INC., (E.D. Pa. 2021).

MOSKOWITZ FAMILY LLC v. GLOBUS MEDICAL, INC. (MOSKOWITZ FAMILY LLC v. GLOBUS MEDICAL, INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related